VivoSeq
Musculoskeletal

Humerus Fracture

12

Pipeline Programs

1

Active Trials

4

Companies Involved

Humerus Fracture is an emerging landscape with 12 programs across 4 companies. The most active players are TLC Biopharmaceuticals, Inc., Kenvue Brands, Almaject. 9 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

33/100

Attrition Rate

33/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

9%ALL OTHERSPeptide19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Trial Status

6

clinical trials

Terminated2 · 33%
Unknown status2 · 33%
Completed1 · 17%
Enrolling by invitation1 · 17%

Trial Activity

6 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)